Cancer Family
Solid Neoplasm
CI-CAN-00000052Explore in graph →
Non-malignant1,823 active trials28 evidence items
- NCIt
- C9292
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000052Explore in graph →
Clinical trials
6,089 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06987500 | A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment | recruiting | Phase 1 / Phase 2 | 132 | Evopoint Biosciences Inc.INDUSTRY | 1 | Jun 6, 2025 | clinicaltrials |
| NCT06653777 | Efficacy of Pemigatinib in Patients With Solid Tumors Characterized by an Alteration of the Gene FGFR in Tumor Cells(AcSé PEMI) | recruiting | Phase 2 | 40 | UNICANCEROTHER | 1 | Jun 5, 2025 |
| NCT06603844 | First-in-human Study of CRB-601-01 to Treat Patients With Advanced Solid Tumor. | recruiting | Phase 1 / Phase 2 | 156 | Corbus Pharmaceuticals Inc.INDUSTRY | 2 | Jun 3, 2025 | clinicaltrials |
| NCT06943820 | AK129 Combination Therapy for Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 230 | AkesoINDUSTRY | 1 | Jun 3, 2025 | clinicaltrials |
| NCT04706715 | LAG3 PET Imaging in Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 41 | University Medical Center GroningenOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT04393298 | A Study to Assess the Safety, Pharmacokinetics and Anti Tumor Activity of UCB6114 Administered Intravenously to Participants With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 93 | UCB Biopharma SRLINDUSTRY | 2 | May 29, 2025 | clinicaltrials |
| NCT04671901 | A Study of Romiplostim to Prevent Low Platelet Counts in Children and Young Adults Receiving Chemotherapy for Solid Tumors | terminated | Phase 2 | 2 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT06208124 | A Study of IMM-6-415 in RAS/RAF Mutant Solid Tumors | completed | Phase 1 / Phase 2 | 30 | Immuneering CorporationINDUSTRY | 1 | May 28, 2025 | clinicaltrials |
| NCT06991478 | SK-NK Injection in Patients With Advanced Solid Tumors Accompanied by Malignant Ascites | not yet recruiting | Phase 1 / Phase 2 | 10 | Tianjin Medical University Cancer Institute and HospitalOTHER | 0 | May 28, 2025 | clinicaltrials |
| NCT06992687 | A Study to Evaluate the Safety and Efficacy of HB0052 in Patients With Advanced Solid Tumors | enrolling by invitation | Phase 1 / Phase 2 | 30 | Shanghai Huaota Biopharmaceutical Co., Ltd.INDUSTRY | 1 | May 28, 2025 | clinicaltrials |
| NCT04442126 | A Study of NM21-1480 in Adult Patients With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 52 | Numab Therapeutics AGINDUSTRY | 3 | May 23, 2025 | clinicaltrials |
| NCT04347226 | Anti-Interleukin-8 (Anti-IL-8) for Patients With COVID-19 | terminated | Phase 2 | 43 | Columbia UniversityOTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT05541822 | To Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetic Profile of ABN401 in Patients With Advanced Solid Tumors Harboring c-MET Dysregulation | recruiting | Phase 2 | 178 | Abion IncINDUSTRY | 3 | May 22, 2025 | clinicaltrials |
| NCT02799095 | A Study of the Effects of ALKS 4230 (Nemvaleukin Alfa) on Subjects With Solid Tumors | completed | Phase 1 / Phase 2 | 243 | Mural Oncology, IncINDUSTRY | 7 | May 21, 2025 | clinicaltrials |
| NCT04555837 | Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer | completed | Phase 1 / Phase 2 | 24 | M.D. Anderson Cancer CenterOTHER | 1 | May 20, 2025 | clinicaltrials |
| NCT05251714 | CFI-402257, a Potent and Selective TTK Inhibitor, in Solid Tumors and With Fulvestrant in Breast Cancer | active not recruiting | Phase 1 / Phase 2 | 44 | Treadwell Therapeutics, IncINDUSTRY | 1 | May 18, 2025 | clinicaltrials |
| NCT04171219 | Talabostat and Pembrolizumab for the Treatment of Advanced Solid Cancers | terminated | Phase 2 | 31 | M.D. Anderson Cancer CenterOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT03673787 | A Trial of Ipatasertib in Combination With Atezolizumab(IceCAP) | active not recruiting | Phase 1 / Phase 2 | 87 | Institute of Cancer Research, United KingdomOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT04914286 | A Study of GFH018 in Combination With Toripalimab in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 148 | Genfleet Therapeutics (Shanghai) Inc.INDUSTRY | 2 | May 14, 2025 | clinicaltrials |
| NCT05144698 | RAPA-201 Therapy of Solid Tumors | recruiting | Phase 1 / Phase 2 | 37 | Rapa Therapeutics LLCINDUSTRY | 1 | May 14, 2025 | clinicaltrials |
| NCT06970132 | Study of SY-5933 Plus CT-707 in Advanced Solid Tumors With KRAS p.G12C Mutation | not yet recruiting | Phase 1 / Phase 2 | 102 | Shouyao Holdings (Beijing) Co. LTDOTHER | 1 | May 14, 2025 | clinicaltrials |
| NCT06971523 | A Phase I/II Clinical Study of CTS3497 in Patients With MTAP Deficient Malignacies | recruiting | Phase 1 / Phase 2 | 224 | CytosinLab Therapeutics Co., Ltd.INDUSTRY | 1 | May 14, 2025 | clinicaltrials |
| NCT04082572 | Pembrolizumab Before Surgery for the Treatment of Mismatch Repair Deficient Locally Advanced Solid Cancers | completed | Phase 2 | 35 | M.D. Anderson Cancer CenterOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT04383938 | Phase 1/2 Study of APR-246 in Combination With Pembrolizumab in Subjects With Solid Tumor Malignancies | completed | Phase 1 / Phase 2 | 40 | Aprea TherapeuticsINDUSTRY | 1 | May 13, 2025 | clinicaltrials |
| NCT03570619 | Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations(IMPACT) | completed | Phase 2 | 56 | University of Michigan Rogel Cancer CenterOTHER | 1 | May 8, 2025 | clinicaltrials |
| NCT04579757 | Surufatinib in Combination With Tislelizumab in Subjects With Advanced Solid Tumors | terminated | Phase 1 / Phase 2 | 87 | HutchmedINDUSTRY | 1 | May 8, 2025 | clinicaltrials |
| NCT04827576 | Study of Magrolimab in Patients With Solid Tumors(ELEVATELung&UC) | terminated | Phase 2 | 106 | Gilead SciencesINDUSTRY | 5 | May 8, 2025 | clinicaltrials |
| NCT05263960 | A Study of CM350 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 248 | Keymed Biosciences Co.LtdINDUSTRY | 1 | May 4, 2025 | clinicaltrials |
| NCT05388435 | Safety, Tolerability, PK/PD & Preliminary Efficacy of SKL27969 in Advanced Solid Tumors Patients | terminated | Phase 1 / Phase 2 | 15 | SK Life Science, Inc.INDUSTRY | 1 | May 4, 2025 | clinicaltrials |
| NCT02632448 | A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | completed | Phase 1 / Phase 2 | 229 | Esperas Pharma Inc.OTHER | 4 | May 2, 2025 | clinicaltrials |
| NCT06955390 | Clinical Trial of HRS-4642 Plus SHR-A2102 in Patients With Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 32 | Henan Cancer HospitalOTHER_GOV | 1 | May 2, 2025 | clinicaltrials |
| NCT06949761 | A Clinical Study to Evaluate the Safety, Tolerability, and Efficacy of QLC1101 in Combination With Other Therapies in the Treatment of Patients With Advanced Solid Tumors Harboring a KRAS G12D Mutation | not yet recruiting | Phase 1 / Phase 2 | 240 | Qilu Pharmaceutical Co., Ltd.INDUSTRY | 0 | Apr 29, 2025 | clinicaltrials |
| NCT00238355 | Voriconazole and Caspofungin Acetate in Treating Invasive Fungal Infections in Patients With Weakened Immune Systems | terminated | Phase 2 | 13 | OHSU Knight Cancer InstituteOTHER | 1 | Apr 27, 2025 | clinicaltrials |
| NCT06947226 | A Clinical Study of 9MW2821 Monotherapy or Combined With Other Anticancer Therapy in Advanced Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 188 | Mabwell (Shanghai) Bioscience Co., Ltd.INDUSTRY | 1 | Apr 27, 2025 | clinicaltrials |
| NCT05736731 | A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors That Express CEA and Have Lost HLA-A*02 Expression(EVEREST-1) | active not recruiting | Phase 1 / Phase 2 | 160 | A2 Biotherapeutics Inc.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT06669975 | A Study of AP402 in HER2-Positive Patients With Locally or Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 85 | AP Biosciences Inc.INDUSTRY | 1 | Apr 25, 2025 | clinicaltrials |
| NCT02717507 | Carvedilol in Preventing Heart Failure in Childhood Cancer Survivors | completed | Phase 2 | 196 | Children's Oncology GroupNETWORK | 4 | Apr 23, 2025 | clinicaltrials |
| NCT05435339 | A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053 Antibody on Malignant Solid Tumors as Monotherapy | terminated | Phase 1 / Phase 2 | 31 | GenmabINDUSTRY | 2 | Apr 22, 2025 | clinicaltrials |
| NCT06895928 | A Trial of SHR-A2102 With Other Antitumor Therapies in Advanced Solid Tumors | recruiting | Phase 2 | 400 | Shanghai Hengrui Pharmaceutical Co., Ltd.INDUSTRY | 1 | Apr 22, 2025 | clinicaltrials |
| NCT06939270 | CD73/AXL Targeted HypoSti.CAR-T Cells in CD73/AXL Positive Advanced/Metastatic Solid Tumors | not yet recruiting | Phase 1 / Phase 2 | 30 | Chinese PLA General HospitalOTHER | 1 | Apr 22, 2025 | clinicaltrials |
| NCT04704154 | A Trial to Learn Whether Regorafenib in Combination With Nivolumab Can Improve Tumor Responses and How Safe it is for Participants With Solid Tumors | completed | Phase 2 | 175 | BayerINDUSTRY | 8 | Apr 18, 2025 | clinicaltrials |
| NCT03610490 | Autologous Tumor Infiltrating Lymphocytes MDA-TIL in Treating Patients With Recurrent or Refractory Ovarian Cancer, Colorectal Cancer, or Pancreatic Ductal Adenocarcinoma | terminated | Phase 2 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Apr 17, 2025 | clinicaltrials |
| NCT06928363 | A First-in-human Study of KY-0301 in Patients With Advanced Solid Tumors. | not yet recruiting | Phase 1 / Phase 2 | 212 | Novatim Immune Therapeutics (Zhejiang) Co., Ltd.INDUSTRY | 0 | Apr 15, 2025 | clinicaltrials |
| NCT04720976 | JAB-3312 Based Combination Therapy in Adult Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 58 | Allist Pharmaceuticals, Inc.INDUSTRY | 1 | Apr 11, 2025 | clinicaltrials |
| NCT04775485 | A Study to Evaluate Tovorafenib in Pediatric and Young Adult Participants With Relapsed or Progressive Low-Grade Glioma and Advance Solid Tumors(FIREFLY-1) | recruiting | Phase 2 | 141 | Day One Biopharmaceuticals, Inc.INDUSTRY | 11 | Apr 10, 2025 | clinicaltrials |
| NCT06431243 | A Clinical Study of Purinostat Mesylate for Injection in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 132 | Chengdu Zenitar Biomedical Technology Co., LtdINDUSTRY | 1 | Apr 10, 2025 | clinicaltrials |
| NCT03179436 | Study of Quavonlimab (MK-1308) in Combination With Pembrolizumab (MK-3475) in Advanced Solid Tumors (MK-1308-001) | completed | Phase 1 / Phase 2 | 415 | Merck Sharp & Dohme LLCINDUSTRY | 16 | Apr 8, 2025 | clinicaltrials |
| NCT03690869 | REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma | terminated | Phase 1 / Phase 2 | 57 | Regeneron PharmaceuticalsINDUSTRY | 1 | Apr 8, 2025 | clinicaltrials |
| NCT03903705 | : A Phase Ib/II Study To Evaluate Fruquintinib Monotherapy Or Plus Sintilimab In Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 348 | HutchmedINDUSTRY | 1 | Apr 6, 2025 | clinicaltrials |
| NCT06911333 | AD1208 in Subjects With Any Progressive, Locally Advanced or Metastatic Solid Tumors(AD1208) | recruiting | Phase 1 / Phase 2 | 36 | Avelos Therapeutics Inc.INDUSTRY | 1 | Apr 4, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jun 6, 2025source: clinicaltrials